BCL2 and acute myeloid leukemia: Iron oxide nanoparticles can thereby increase the AML cell susceptibility to other antileukemic agents, e.g., increased susceptibility of monocytic ROS-high AML cells to the BCL2-inhibitor venetoclax [290] and the conventional cytotoxic drug cytarabine [289].